Cargando…

World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are major causes of hepatocellular carcinoma (HCC). In order to assess the relative contribution of HBV and HCV to HCC worldwide, and identify changes over time, we conducted a systematic review of case series published up to the year 2014. Eligibl...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Martel, Catherine, Maucort‐Boulch, Delphine, Plummer, Martyn, Franceschi, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Hepatobiliary Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019261/ https://www.ncbi.nlm.nih.gov/pubmed/26146815 http://dx.doi.org/10.1002/hep.27969

Ejemplares similares

Autophagy Suppresses Tumorigenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma Through Degradation of MicroRNA-224
por: Lan, Sheng-Hui, et al.
Publicado: (2014)

Signal transducer and activator of transcription 3‐mediated CD133 up‐regulation contributes to promotion of hepatocellular carcinoma
por: Won, Cheolhee, et al.
Publicado: (2015)

Dysregulated serum response factor triggers formation of hepatocellular carcinoma
por: Ohrnberger, Stefan, et al.
Publicado: (2015)

Evaluation of Abdominal Ultrasonography Mass Screening for Hepatocellular Carcinoma in Taiwan
por: Yeh, Yen-Po, et al.
Publicado: (2014)

A Computed Tomography Radiogenomic Biomarker Predicts Microvascular Invasion and Clinical Outcomes in Hepatocellular Carcinoma
por: Banerjee, Sudeep, et al.
Publicado: (2015)

Immunodominance and functional alterations of tumor‐associated antigen‐specific CD8(+) T‐cell responses in hepatocellular carcinoma
por: Flecken, Tobias, et al.
Publicado: (2014)

Actin‐like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial‐mesenchymal transition
por: Xiao, Shuai, et al.
Publicado: (2016)

CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation–induced cell death in hepatocellular carcinoma
por: Lu, Guo-Dong, et al.
Publicado: (2015)

Hepatocellular carcinoma repression by TNFα‐mediated synergistic lethal effect of mitosis defect‐induced senescence and cell death sensitization
por: Li, Dan, et al.
Publicado: (2016)

Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR‐338‐3p‐PKLR axis in hepatocellular carcinoma
por: Nie, Huizhen, et al.
Publicado: (2015)

Down‐regulation of TIMP2 by HIF‐1α/miR‐210/HIF‐3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma
por: Kai, Alan Ka‐Lun, et al.
Publicado: (2016)

MicroRNA-494 is a master epigenetic regulator of multiple invasion-suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors
por: Chuang, Kuang-Hsiang, et al.
Publicado: (2015)

Lineage-dependent effects of aryl hydrocarbon receptor agonists contribute to liver tumorigenesis
por: Harrill, Joshua A, et al.
Publicado: (2015)

The Linear ubiquitin chain assembly complex acts as a liver tumor suppressor and inhibits hepatocyte apoptosis and hepatitis
por: Shimizu, Yutaka, et al.
Publicado: (2017)

Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2
por: Liu, Runping, et al.
Publicado: (2014)

MicroRNA-494 Within an Oncogenic MicroRNA Megacluster Regulates G(1)/S Transition in Liver Tumorigenesis Through Suppression of Mutated in Colorectal Cancer
por: Lim, Lionel, et al.
Publicado: (2014)

Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer
por: Aleksandrova, Krasimira, et al.
Publicado: (2014)

Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma
por: Andresen, Kim, et al.
Publicado: (2015)

MAF1 suppresses AKT‐mTOR signaling and liver cancer through activation of PTEN transcription
por: Li, Yue, et al.
Publicado: (2016)

Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance
por: Mähringer‐Kunz, Aline, et al.
Publicado: (2021)

The Comparison of Surgical Margins and Type of Hepatic Resection for Hepatocellular Carcinoma With Microvascular Invasion
por: Liu, Jianwei, et al.
Publicado: (2023)

Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients
por: Owusu Sekyere, Solomon, et al.
Publicado: (2021)

Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices
por: Klink, Andrew J, et al.
Publicado: (2022)

TAC score better predicts survival than the BCLC following resection of hepatocellular carcinoma
por: Lima, Henrique A., et al.
Publicado: (2022)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

New concepts in the treatment of hepatocellular carcinoma
por: Sidali, Sabrina, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters
por: Sidali, Sabrina, et al.
Publicado: (2022)

Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
por: Li, Xiaomi, et al.
Publicado: (2023)

Dynamic contrast-enhanced CT and clinical features of sarcomatoid hepatocellular carcinoma
por: He, Guangming, et al.
Publicado: (2023)

Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: A systematic review
por: Norero, Blanca, et al.
Publicado: (2023)

DCE-MRI-based radiomics in predicting angiopoietin-2 expression in hepatocellular carcinoma
por: Zheng, Jing, et al.
Publicado: (2023)

Association of Tumor Cell Metabolic Subtype and Immune Response With the Clinical Course of Hepatocellular Carcinoma
por: Wei, Xiaolin, et al.
Publicado: (2023)

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
por: Müller, Lukas, et al.
Publicado: (2021)

High pretreatment static and dynamic alpha‐fetoprotein values predict reduced overall survival in hepatocellular carcinoma
por: Czauderna, Carolin, et al.
Publicado: (2021)

Contrast-enhanced ultrasound for screening hepatocellular carcinoma: an implemented program at a semi-rural academic center
por: Motz, Victoria L., et al.
Publicado: (2021)

Response evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: magnetic resonance imaging findings
por: Mai, Zhijun, et al.
Publicado: (2023)

Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
por: Woei‐A‐Jin, F.J. Sherida H., et al.
Publicado: (2021)

Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Fukushima, Taito, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_naetso278oio4p8a8uaq3kpe18